Journal September 25, 2026 6 min read

What markers track continuous glucose monitoring?

Continuous glucose monitoring tracks interstitial glucose as its primary marker, with time in range, glucose variability and hypoglycaemia burden as derived endpoints. This page summarises the trial-level evidence for th

peptides-pro Editorial

Continuous glucose monitoring (CGM) is a class of minimally invasive biosensing systems that estimate glucose concentration in interstitial fluid rather than in blood. The markers it reports are therefore not a single analyte but a set: interstitial glucose concentration sampled at fixed intervals, and the derived summary metrics calculated from that time series — time in range (TIR), time below range, time above range, mean glucose, and indices of glycaemic variability. CGM is used as a monitoring modality rather than a therapeutic agent, and in the studies below it appears both as an intervention (CGM versus self-monitoring of blood glucose) and as an instrument for measuring the effect of some other intervention. The evidence block does not supply a sequence, formula or molecular weight for CGM systems, because these are devices rather than defined chemical entities.

The physiological signal CGM depends on is interstitial glucose, which equilibrates with plasma glucose across capillary endothelium and is subject to a lag that varies with perfusion and tissue state. The work described in the evidence centres on glycaemic control as an endpoint family — glucose homeostasis, insulin sensitivity and metabolic flexibility — rather than on a single receptor or pathway.

Research Studies

Dorzagliatin and glycaemic homeostasis in type 2 diabetes with chronic renal insufficiency

A prospective, randomised, active-controlled, multicentre trial is planned to enrol 206 patients with type 2 diabetes mellitus complicated by moderate to severe chronic renal insufficiency, defined as an estimated glomerular filtration rate below 45 mL/min/1.73 m². The study is designed to test whether dorzagliatin improves glycaemic homeostasis in this population and to compare it with linagliptin. After screening, participants enter a two-week run-in of diet and exercise control together with continuous glucose monitoring, which places CGM in the role of baseline characterisation rather than the intervention under test [1].

CGM versus self-monitoring of blood glucose in gestational diabetes

Gestational diabetes mellitus is first diagnosed during pregnancy and is associated with macrosomia, a higher likelihood of insulin treatment and increased risk of hypertensive complications in the mother. Standard monitoring in this population is self-monitoring of blood glucose, which requires repeated finger-prick sampling through the day. The trial in the evidence block compares CGM against that standard in women with gestational diabetes, with glycaemic control as the outcome of interest [2].

Insulin glargine dosing frequency and glucose time in range in pregestational diabetes

A randomised study in pregnant patients with pregestational diabetes assigns participants to insulin glargine once daily or twice daily, with continuous glucose monitoring used to track blood glucose. The primary question is whether twice-daily dosing produces better glucose time in range than once-daily dosing [4]. Here CGM supplies the endpoint metric rather than the intervention.

Metformin withdrawal and metabolic flexibility in metabolic syndrome

This trial examines what happens when metformin is interrupted for 14 days in adults with metabolic syndrome who take it as part of usual care. The scenarios motivating the question are ordinary ones — missed doses, access problems, travel, or planned short-term discontinuation for clinical reasons. The study asks whether short-term cessation produces rapid changes in glucose metabolism or whether prior metformin effects persist through the interruption, with insulin sensitivity, glucose control and metabolic flexibility as the measured domains [6].

Accu-Chek SmartGuide CGM with the Predict App and person-reported outcomes

A controlled pre-post trial tests the Accu-Chek SmartGuide CGM system together with its predictive app in adults with type 1 diabetes or insulin-treated type 2 diabetes. The questions concern fear of hypoglycaemia, sleep quality, confidence in preventing hypoglycaemia, diabetes-related distress and diabetes empowerment, alongside glucose levels and patterns of device use [7]. This is the clearest example in the evidence of CGM-derived data being paired with behavioural and psychological endpoints rather than glycaemic ones alone.

Time-restricted eating and weight-loss maintenance

A multi-centre two-arm randomised controlled trial across six regions in China targets overweight or obese adults who have recently lost at least 5% of body weight. It compares a 10-hour daily time-restricted eating regimen against standard weight-maintenance counselling for prevention of weight regain, with both arms receiving the same frequency and intensity of nutritional counselling [8].

Chronic pancreatitis cohort with longitudinal ERCP

The BILE-CP study is a prospective longitudinal cohort in Hangzhou, Zhejiang Province, China, planning to enrol 1,500 patients with chronic pancreatitis for follow-up scheduled every six months. It spans the full disease course and tracks in depth a sub-cohort undergoing ERCP. Baseline and follow-up visits collect multidimensional data including sociodemographics, diet and lifestyle, emotional status and sleep [3].

Multilevel exercise response in elite rowers

An observational study of thirty members of the Polish Youth National Rowing Team, aged 19 to 24, evaluates physiological, molecular, metabolic, intestinal, immunological and psychophysiological responses to rowing-specific exercise across two training periods. During the competitive phase participants perform a 2000-m maximal rowing effort, and the study examines integrated adaptive mechanisms relating to mitochondrial function, metabolic regulation, intestinal permeability, immune activation, DNA damage response and psychological status [5].

Comparison of monitoring and endpoint roles across studies

Study population	Role of CGM	Primary marker domain
T2DM with chronic renal insufficiency [1]	Run-in characterisation	Glycaemic homeostasis
Gestational diabetes [2]	Intervention under comparison	Glycaemic control
Pregestational diabetes [4]	Endpoint measurement	Time in range
Type 1 or insulin-treated T2DM [7]	Intervention plus predictive app	Person-reported outcomes and glucose

Supporting reports

Several reports in the evidence describe CGM in narrower or non-trial settings. A randomised crossover study examined acute postprandial endocrine and glycaemic kinetics following individual macronutrient boluses in people adapted to a low-carbohydrate diet [9]. Two cats with diabetes mellitus and Cushing syndrome were managed with insulin glargine, nutritional therapy and continuous glucose monitoring, with hypercortisolism suspected on the basis of severe hypertension and insulin resistance [10]. A case report described symptomatic hypoglycaemia after surgical treatment for median arcuate ligament syndrome, with predominantly postprandial hypoglycaemia following higher-carbohydrate meals and findings suggesting postprandial hyperinsulinaemic hypoglycaemia [11]. A hypothesis-generating narrative review proposed CGM as a candidate precision tool for cardiovascular prevention and healthy longevity, noting that subclinical glucose dysregulation is undetectable by conventional screening in apparently healthy individuals and that postprandial excursions occur even within the normal glycaemic range [12]. These are supporting observations; the animal and single-case reports should be read as such.

If you are reading this for personal health reasons

The materials described here are supplied for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound or a monitoring device for their own health should speak to a licensed clinician.